The efficacy and safety of precision repetitive transcranial magnetic stimulation in alleviating motor symptoms in Parkinson's disease (PRESS-PD): a randomized, double-blind, multicenter, placebo-controlled trial.
The efficacy and safety of precision repetitive transcranial magnetic stimulation in alleviating motor symptoms in Parkinson's disease (PRESS-PD): a randomized, double-blind, multicenter, placebo-controlled trial.
Where did the research take place?
Possible study sites were matched from the text; these need review.
CN · Possible study site · country only
The study is expected to be conducted across eight medical centers in China, commencing in 2024 and concluding in 2026.Location evidence
Hefei, CN · Author affiliation
Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.Location evidence
Beijing, CN · Author affiliation
Peking University Sixth Hospital, Beijing, 100083, China.Location evidence
Dalian, CN · Author affiliation
The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, China.Location evidence
Chengdu, CN · Author affiliation
Chengdu Second People's Hospital, Chengdu, 610017, China.Location evidence
Nanjing, CN · Author affiliation
Jiangsu Province Hospital, Nanjing, 210029, China.Location evidence
Xuzhou, CN · Author affiliation
Xuzhou Central Hospital, Xuzhou, 221009, China.Location evidence
CN · Author affiliation · country only
Suzhou Municipal Hospital, Suzhou, 234000, China.Location evidence
Follow the study behind this paper
Testing targeted magnetic brain stimulation for movement symptoms
The registry links this paper to the study.
A plain-language reading has not been prepared for this paper yet.
Original abstract
BACKGROUND: As an innovative noninvasive neuromodulation technology, repetitive transcranial magnetic stimulation (rTMS) has demonstrated efficacy in improving motor symptoms in patients with Parkinson's disease (PD). The supplementary motor area (SMA) has been identified as a brain region significantly associated with motor symptoms in PD patients. However, no large-sample clinical studies have yet established the clinical efficacy of rTMS, guided by neuroimaging navigation, targeting the SMA in patients with PD. METHODS: This study describes a randomized, double-blind, placebo-controlled, multicenter study designed to recruit 290 patients with primary PD. Participants will be randomly assigned to receive either real stimulation or sham stimulation, with the left SMA undergoing 7 days of continuous theta-burst stimulation (cTBS). The primary outcome measure is the changes in MDS-UPDRS III scores assessed from baseline to the end of 7-day treatment (on day 8). The secondary outcome is changes in other clinical symptom scores from baseline to day 8 and weeks 5 and 9. The study is expected to be conducted across eight medical centers in China, commencing in 2024 and concluding in 2026. DISCUSSION: This study will evaluate the clinical efficacy and safety of cTBS targeting the left SMA in patients with PD. These findings may offer a new therapeutic approach for PD. TRIAL REGISTRATION: ClinicalTrials.gov NCT06383247 (registered April 2024).